93 related articles for article (PubMed ID: 26118369)
1. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.
Fujii-Nishimura Y; Nishiyama R; Kitago M; Masugi Y; Ueno A; Aiura K; Kawachi S; Kawaida M; Abe Y; Shinoda M; Itano O; Tanimoto A; Sakamoto M; Kitagawa Y
Keio J Med; 2015; 64(2):26-31. PubMed ID: 26118369
[TBL] [Abstract][Full Text] [Related]
2. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
5. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
Homma Y; Honda G; Sakamoto K; Kurata M; Honjo M; Hirata Y; Shinya S
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1166-1170. PubMed ID: 27760934
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
[TBL] [Abstract][Full Text] [Related]
9. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Takamura M; Nio Y; Yamasawa K; Dong M; Yamaguchi K; Itakura M
Anticancer Drugs; 2002 Jan; 13(1):75-85. PubMed ID: 11914644
[TBL] [Abstract][Full Text] [Related]
10. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.
Sharma G; Whang EE; Ruan DT; Ito H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1229-37. PubMed ID: 26152276
[TBL] [Abstract][Full Text] [Related]
12. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
13. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
14. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
15. Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer.
Tsuruga Y; Kamachi H; Wakayama K; Kakisaka T; Yokoo H; Kamiyama T; Taketomi A
World J Gastroenterol; 2013 Apr; 19(16):2569-73. PubMed ID: 23674861
[TBL] [Abstract][Full Text] [Related]
16. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
17. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy].
Miyahara Y; Okamura D; Nishida T; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Suzuki D; Sakai N; Kagawa S; Miyazaki M
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2382-4. PubMed ID: 26805371
[TBL] [Abstract][Full Text] [Related]
18. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
[TBL] [Abstract][Full Text] [Related]
19. Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results.
Kawada N; Tanaka S; Uehara H; Katayama K; Hosoki T; Takami M; Tomita Y
Hepatogastroenterology; 2014; 61(130):480-3. PubMed ID: 24901166
[TBL] [Abstract][Full Text] [Related]
20. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
